Alluvi, formerly BI 4744, presents a notable breakthrough in obesity care. This dual stimulator targeting both GLP-1 and GIP receptors demonstrates impressive results in clinical trials, potentially outperforming https://wise-social.com/story7732804/alluvi-a-comprehensive-investigation-into-retatrutide-s-potential